Comparison of double (360 mg) ticagrelor loading dose with standard (60 mg) prasugrel loading dose in ST-elevation myocardial infarction patients: The Rapid Activity of Platelet Inhibitor Drugs (RAPID) primary PCI 2 study

American Heart Journal

Volumn 167, Issue 6, 2014, Pages 909-914

  Parodi, Guido ^a   Bellandi, Benedetta ^a   Valenti, Renato ^a   Migliorini, Angela ^a   Marcucci, Rossella ^b   Carrabba, Nazario ^a   Giurlani, Letizia ^a   Gensini, Gian Franco ^a,b,c   Abbate, Rosanna ^b   Antoniucci, David ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MORPHINE; PRASUGREL; TICAGRELOR;

ADULT; AGED; ARTICLE; BLEEDING; BRADYCARDIA; CEREBROVASCULAR ACCIDENT; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; DYSPNEA; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; HYPERTRANSAMINASEMIA; LOADING DRUG DOSE; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; PRIMARY PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION ANALYZER; TREATMENT OUTCOME;

ADENOSINE; AGED; ASPIRIN; COMBINED MODALITY THERAPY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PIPERAZINES; PLATELET ACTIVATION; PLATELET AGGREGATION INHIBITORS; PREMEDICATION; PURINERGIC P2Y RECEPTOR ANTAGONISTS; THIOPHENES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901757847     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2014.03.011     Document Type: Article

References (14)

1. G. Steg, S.K. James, and D. Atar et al. ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation Eur Heart J 33 2012 2569 2619
2. P.T. O'Gara, F.G. Kushner, and D.D. Ascheim et al. ACCF/AHA guideline for the management of ST-elevation myocardial infarction: executive summary. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. AHA/ACC STEMI guidelines 2013 Circulation 127 2013 529 555
3. M. Valgimigli, M. Tebaldi, and G. Campo et al. Prasugrel versus tirofiban bolus with or without short post-bolus infusion with or without concomitant prasugrel administration in patients with myocardial infarction undergoing coronary stenting: the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given at loading dOse) trial. JACC Cardiovasc Interv 5 2012 268 277
4. D. Alexopoulos, I. Xanthopoulou, and V. Gkizas et al. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction Circ Cardiovasc Interv 5 2012 797 804
5. G. Parodi, R. Valenti, and B. Bellandi et al. Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study J Am Coll Cardiol 61 2013 1601 1606
6. R. Teng, and K. Butler Pharmacokinetics, pharmacodynamics, tolerability and safety of single ascending doses of ticagrelor, a reversibly binding oral P2Y12 receptor antagonist, in healthy subjects Eur J Clin Pharmacol 66 2012 487 496
7. C.P. Cannon, S. Husted, and R.A. Harrington et al. Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome J Am Coll Cardiol 50 2007 1844 1851 (Pubitemid 350007959)
8. S. Husted Husted, H. Emanuelsson, and S. Heptinstall et al. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin Eur Heart J 27 2006 1038 1047
9. R. Marcucci, A.M. Gori, and R. Paniccia et al. Cardiovascular death and nonfatal myocardial infarction in acute coronary syndrome patients receiving coronary stenting are predicted by residual platelet reactivity to ADP detected by a point-of-care assay: a 12-month follow-up Circulation 119 2009 237 242
10. U.S. Tantry, L. Bonello, and D. Aradi et al. Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding J Am Coll Cardiol 62 2013 2261 2273
11. H.L. Nielsen, S.D. Kristensen, and S.S. Thygesen et al. Aspirin response evaluated by the VerifyNow Aspirin System and light transmission aggregometry Thromb Res 123 2 2008 267 273
12. D. Alexopoulos, V. Gkizas, and S. Patsilinakos et al. Double vs standard loading dose of ticagrelor: onset of antiplatelet action in patients with STEMI undergoing primary PCI J Am Coll Cardiol 62 2013 940 941
13. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group Lancet 2 1988 349 360
14. T. Grosser, S. Fries, and J.A. Lawson et al. Drug resistance and pseudoresistance: an unintended consequence of enteric coating aspirin Circulation 127 2013 377 385